Source:http://linkedlifedata.com/resource/pubmed/id/16499877
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2006-3-13
|
pubmed:abstractText |
It is now well-established that P-glycoprotein 170 (P-gp), an efflux pump involved in multidrug resistance (MDR) is overexpressed at the plasma membrane of doxorubicin-resistant K562 leukemia cells. Nevertheless, several results suggested: (i) that P-gp-mediated drug efflux was not the only mechanism involved in resistance; (ii) that intracellular compartments could accumulate the drug, preventing it from reaching its nuclear targets; (iii) that agents able to reverse multidrug resistance may lead to intracellular drug redistribution. We have studied the localization of P-gp in mitochondria as well as its functional properties in this compartment. Using several monoclonal antibodies (MoAbs) directed against different P-gp epitopes, a protein was detected in the cytoplasm of two doxorubicin-resistant K562 sublines and, by confocal laser scanning microscopy, this protein was shown to co-localize in the Golgi apparatus and in mitochondria, in equivalent proportions. Purified mitochondria were isolated from K562 cell variants; the presence of a protein of about 170 kDa and reacting with several anti-P-gp antibodies was assessed in MDR cells by Western blotting and flow cytometry. Functional assays have shown that mitochondrial P-gp was involved in doxorubicin accumulation inside the organelle but not in its efflux, suggesting an orientation of P-gp in the mitochondrial membrane inverse to that observed in the plasma membrane. A potential role for mitochondrial P-gp in MDR cells would be to protect the nucleus from doxorubicin. This is the first demonstration of the presence and functional activity of P-gp in mitochondria of MDR cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0006-2952
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
14
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1162-74
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16499877-Antibiotics, Antineoplastic,
pubmed-meshheading:16499877-Antibodies, Monoclonal,
pubmed-meshheading:16499877-Blotting, Western,
pubmed-meshheading:16499877-Cell Nucleus,
pubmed-meshheading:16499877-Doxorubicin,
pubmed-meshheading:16499877-Drug Resistance, Multiple,
pubmed-meshheading:16499877-Drug Resistance, Neoplasm,
pubmed-meshheading:16499877-Flow Cytometry,
pubmed-meshheading:16499877-Humans,
pubmed-meshheading:16499877-K562 Cells,
pubmed-meshheading:16499877-Microscopy, Confocal,
pubmed-meshheading:16499877-Mitochondria,
pubmed-meshheading:16499877-P-Glycoprotein
|
pubmed:year |
2006
|
pubmed:articleTitle |
Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
|
pubmed:affiliation |
Laboratoire de Physiologie Mitochondriale, EA 3842 Faculté de Médecine, Limoges, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|